DelveInsight’s “Cystinuria Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Cystinuria, historical and forecasted epidemiology as well as the Cystinuria market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Cystinuria Overview
Cystinuria is an inheritable autosomal recessive disorder of amino acid transport affecting the epithelial cells of the renal tubules and gastrointestinal tract. It is characterized by abnormal concentrations of cystine and the other dibasic amino acids in the urine, resulting in a risk of renal stone formation because of the low solubility of cystine in urine. According to the recent advances in molecular genetics, two genes have been identified as responsible for this disease (SLC3A1 and SLC7A9), but other unknown genes may be involved in cystinuria. We assessed the presence of cystinuria in 2086 consecutive patients with renal stones by using the cyanide-nitroprusside test (Brand’s test). According to our experience, this screening test should be performed in all patients at the onset of renal stone disease in order to avoid a delay in the possible diagnosis of cystinuria. In fact, cystinuric patients often have mixed calculi composed of substances other than cystine that can disguise the presence of cystininuria that is so diagnosed many years after the onset of the initial symptoms.
Cystinuria Epidemiology Insights
-
The disorder occurs in approximately 1 in 7,000 to 1 in 10,000 people in the United States. The prevalence of cystinuria varies in different countries.
-
The estimated prevalence of cystinuria is about 1 in 10,000, equating to approximately 33,000 cases annually. Worldwide, the overall prevalence is 1 person per 7000 population but varies significantly by population.
Click here to learn more about the Cystinuria Market Landscape
The Report Covers the Cystinuria Epidemiology Segmented by:
-
Cystinuria prevalent cases
-
Cystinuria incident cases
-
Cystinuria treatment cases
-
Cystinuria diagnosed cases
Cystinuria Market Outlook
Cystinuria treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for Cystinuria may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. The first step in treating Cystinuria is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and remove as much tumor as possible safely. Cystinuria surgery is performed to achieve a “maximum safe resection,” or remove as much of the tumor as possible without causing lasting neurological damage.
Key Companies Working in the Cystinuria Market
Revive Therapeutics
Otsuka Pharmaceutical
Eloxx Pharmaceuticals
Travere Therapeutics
Advicenne
And many others
Cystinuria Therapies Covered and Analyzed in the Report
-
Tiopronin
-
ADV7103
-
Bucillamine
-
Dapagliflozin
And many others
Learn more about the Key Companies and Emerging Therapies in the Cystinuria Market
Table of Contents
-
Key Insights
-
Cystinuria Introduction
-
Executive Summary of Cystinuria
-
Disease Background and Overview
-
Epidemiology and patient population
-
Cystinuria Emerging Therapies
-
Cystinuria Market Outlook
-
Market Access and Reimbursement of Therapies
-
Market Drivers
-
Market Barriers
-
Appendix
-
Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
Learn about the detailed offerings of the report @ Cystinuria Market Outlook
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services